Abstract
Though natriuretic peptides (NPs) have been shown to be very powerful prognostic markers in many cardiac diseases or in general population their role in patients with atrial fibrillation (AF) has not been established yet. Atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) play both regulatory and modulatory roles in the cardiovascular system. There is conflicting data on the predictive value of NPs on a cardioversion (CV) outcome and on the risk of developing AF. The prognostic usefulness of each peptide seems to be different. A poor correlation between baseline plasma ANP levels and long-term outcome of CV was described. However, a relationship between exercise-induced increase in ANP concentrations before CV, and successful CV and sinus rhythm maintenance, has been found. In contrast, elevated plasma BNP levels baseline and during exercise testing are associated with unsuccessful outcome in patients undergoing CV.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
